Genetic diagnosis of neurofibromatosis type 1

Targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis

Yah Huei Wu-Chou, Tzu Chao Hung, Yin Ting Lin, Hsing Wen Cheng, Ju Li Lin, Chih Hung Lin, Chung Chih Yu, Kuo Ting Chen, Tu Hsueh Yeh, Yu Ray Chen

Research output: Contribution to journalArticle

Abstract

Background: Neurofibromatosis type 1 (NF1) is a dominantly inherited tumor predisposition syndrome that targets the peripheral nervous system. It is caused by mutations of the NF1 gene which serve as a negative regulator of the cellular Ras/MAPK (mitogen-activated protein kinases) signaling pathway. Owing to the complexity in some parts of clinical diagnoses and the need for better understanding of its molecular relationships, a genetic characterization of this disorder will be helpful in the clinical setting. Methods: In this study, we present a customized targeted gene panel of NF1/KRAS/BRAF/p53 and SPRED1 genes combined with Multiple Ligation-Dependent Probe Amplification analysis for the NF1 mutation screening in a cohort of patients clinically suspected as NF1. Results: In this study, we identified 73 NF1 mutations and two BRAF novel variants from 100 NF1 patients who were suspected as having NF1. These genetic alterations are heterogeneous and distribute in a complicated way without clustering in either cysteine-serine-rich domain or within the GAP-related domain. We also detected fifteen multi-exon deletions within the NF1 gene by MLPA Analysis. Conclusions: Our results suggested that a genetic screening using a NGS panel with high coverage of Ras-signaling components combined with Multiple Ligation-Dependent Probe Amplification analysis will enable differential diagnosis of patients with overlapping clinical features.

Original languageEnglish
Article number72
JournalJournal of Biomedical Science
Volume25
Issue number1
DOIs
Publication statusPublished - Oct 5 2018
Externally publishedYes

Fingerprint

Neurofibromatosis 1
Ligation
Amplification
Genes
Screening
Neurofibromatosis 1 Genes
Neurology
Mitogen-Activated Protein Kinases
Serine
Cysteine
Tumors
Exons
Mutation
Inborn Genetic Diseases
p53 Genes
Peripheral Nervous System
Genetic Testing
Cluster Analysis
Differential Diagnosis

Keywords

  • Genetic counseling
  • MLPA
  • Neurofibromatosis type 1
  • RASopathies
  • Targeted NGS

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

Genetic diagnosis of neurofibromatosis type 1 : Targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis. / Wu-Chou, Yah Huei; Hung, Tzu Chao; Lin, Yin Ting; Cheng, Hsing Wen; Lin, Ju Li; Lin, Chih Hung; Yu, Chung Chih; Chen, Kuo Ting; Yeh, Tu Hsueh; Chen, Yu Ray.

In: Journal of Biomedical Science, Vol. 25, No. 1, 72, 05.10.2018.

Research output: Contribution to journalArticle

Wu-Chou, Yah Huei ; Hung, Tzu Chao ; Lin, Yin Ting ; Cheng, Hsing Wen ; Lin, Ju Li ; Lin, Chih Hung ; Yu, Chung Chih ; Chen, Kuo Ting ; Yeh, Tu Hsueh ; Chen, Yu Ray. / Genetic diagnosis of neurofibromatosis type 1 : Targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis. In: Journal of Biomedical Science. 2018 ; Vol. 25, No. 1.
@article{5db00eee72a74a54882aff70c469d4a2,
title = "Genetic diagnosis of neurofibromatosis type 1: Targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis",
abstract = "Background: Neurofibromatosis type 1 (NF1) is a dominantly inherited tumor predisposition syndrome that targets the peripheral nervous system. It is caused by mutations of the NF1 gene which serve as a negative regulator of the cellular Ras/MAPK (mitogen-activated protein kinases) signaling pathway. Owing to the complexity in some parts of clinical diagnoses and the need for better understanding of its molecular relationships, a genetic characterization of this disorder will be helpful in the clinical setting. Methods: In this study, we present a customized targeted gene panel of NF1/KRAS/BRAF/p53 and SPRED1 genes combined with Multiple Ligation-Dependent Probe Amplification analysis for the NF1 mutation screening in a cohort of patients clinically suspected as NF1. Results: In this study, we identified 73 NF1 mutations and two BRAF novel variants from 100 NF1 patients who were suspected as having NF1. These genetic alterations are heterogeneous and distribute in a complicated way without clustering in either cysteine-serine-rich domain or within the GAP-related domain. We also detected fifteen multi-exon deletions within the NF1 gene by MLPA Analysis. Conclusions: Our results suggested that a genetic screening using a NGS panel with high coverage of Ras-signaling components combined with Multiple Ligation-Dependent Probe Amplification analysis will enable differential diagnosis of patients with overlapping clinical features.",
keywords = "Genetic counseling, MLPA, Neurofibromatosis type 1, RASopathies, Targeted NGS, Genetic counseling, MLPA, Neurofibromatosis type 1, RASopathies, Targeted NGS",
author = "Wu-Chou, {Yah Huei} and Hung, {Tzu Chao} and Lin, {Yin Ting} and Cheng, {Hsing Wen} and Lin, {Ju Li} and Lin, {Chih Hung} and Yu, {Chung Chih} and Chen, {Kuo Ting} and Yeh, {Tu Hsueh} and Chen, {Yu Ray}",
year = "2018",
month = "10",
day = "5",
doi = "10.1186/s12929-018-0474-9",
language = "English",
volume = "25",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Genetic diagnosis of neurofibromatosis type 1

T2 - Targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis

AU - Wu-Chou, Yah Huei

AU - Hung, Tzu Chao

AU - Lin, Yin Ting

AU - Cheng, Hsing Wen

AU - Lin, Ju Li

AU - Lin, Chih Hung

AU - Yu, Chung Chih

AU - Chen, Kuo Ting

AU - Yeh, Tu Hsueh

AU - Chen, Yu Ray

PY - 2018/10/5

Y1 - 2018/10/5

N2 - Background: Neurofibromatosis type 1 (NF1) is a dominantly inherited tumor predisposition syndrome that targets the peripheral nervous system. It is caused by mutations of the NF1 gene which serve as a negative regulator of the cellular Ras/MAPK (mitogen-activated protein kinases) signaling pathway. Owing to the complexity in some parts of clinical diagnoses and the need for better understanding of its molecular relationships, a genetic characterization of this disorder will be helpful in the clinical setting. Methods: In this study, we present a customized targeted gene panel of NF1/KRAS/BRAF/p53 and SPRED1 genes combined with Multiple Ligation-Dependent Probe Amplification analysis for the NF1 mutation screening in a cohort of patients clinically suspected as NF1. Results: In this study, we identified 73 NF1 mutations and two BRAF novel variants from 100 NF1 patients who were suspected as having NF1. These genetic alterations are heterogeneous and distribute in a complicated way without clustering in either cysteine-serine-rich domain or within the GAP-related domain. We also detected fifteen multi-exon deletions within the NF1 gene by MLPA Analysis. Conclusions: Our results suggested that a genetic screening using a NGS panel with high coverage of Ras-signaling components combined with Multiple Ligation-Dependent Probe Amplification analysis will enable differential diagnosis of patients with overlapping clinical features.

AB - Background: Neurofibromatosis type 1 (NF1) is a dominantly inherited tumor predisposition syndrome that targets the peripheral nervous system. It is caused by mutations of the NF1 gene which serve as a negative regulator of the cellular Ras/MAPK (mitogen-activated protein kinases) signaling pathway. Owing to the complexity in some parts of clinical diagnoses and the need for better understanding of its molecular relationships, a genetic characterization of this disorder will be helpful in the clinical setting. Methods: In this study, we present a customized targeted gene panel of NF1/KRAS/BRAF/p53 and SPRED1 genes combined with Multiple Ligation-Dependent Probe Amplification analysis for the NF1 mutation screening in a cohort of patients clinically suspected as NF1. Results: In this study, we identified 73 NF1 mutations and two BRAF novel variants from 100 NF1 patients who were suspected as having NF1. These genetic alterations are heterogeneous and distribute in a complicated way without clustering in either cysteine-serine-rich domain or within the GAP-related domain. We also detected fifteen multi-exon deletions within the NF1 gene by MLPA Analysis. Conclusions: Our results suggested that a genetic screening using a NGS panel with high coverage of Ras-signaling components combined with Multiple Ligation-Dependent Probe Amplification analysis will enable differential diagnosis of patients with overlapping clinical features.

KW - Genetic counseling

KW - MLPA

KW - Neurofibromatosis type 1

KW - RASopathies

KW - Targeted NGS

KW - Genetic counseling

KW - MLPA

KW - Neurofibromatosis type 1

KW - RASopathies

KW - Targeted NGS

UR - http://www.scopus.com/inward/record.url?scp=85054441764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054441764&partnerID=8YFLogxK

U2 - 10.1186/s12929-018-0474-9

DO - 10.1186/s12929-018-0474-9

M3 - Article

VL - 25

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 1

M1 - 72

ER -